MedElevator
Войти в исследования Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
A fovea-centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teijeira-Portas Sara, Murueta-Goyena Ane, Zamora-Otaola Aitor, Perez Raquel, Fernandez Manuel, Almeida Javier, Blanco Elisa, Gonzalez Tirso, Barrenechea Maitane, Ayala Unai, Zuazo Garazi, Gomez-Esteban Juan Carlos, Acera Marian, Del Pino Rocío, Gabilondo Iñigo
Аннотация
INTRODUCTION: Blood biomarkers detect Alzheimer's disease (AD), but tissue correlates of early tau pathology and glial activation remain unclear. We investigated whether multimodal retinal measures capture a focal prodromal AD (pAD) pattern linked to plasma biomarkers.
METHODS: Thirty-eight individuals with pAD and 40 controls underwent optical coherence tomography (OCT), OCT-angiography (OCT-A), and electroretinography (ERG). Plasma p-tau217, p-tau181, glial fibrillary acidic protein (GFAP) Aβ42 and Aβ40 were quantified, adjusting for age, sex, and vascular risk factors.
RESULTS: Between-group differences were restricted to parafoveal OCT-A measures. Within the pAD group, higher p-tau217/Aβ42 and GFAP showed consistent associations with foveal measures: increased ganglion cell-inner plexiform layer (GCIPL) thickness, capillary density, altered foveal avascular zone (FAZ), and reduced photopic negative-response amplitude. These associations were absent in controls. Mediation analyses indicated that foveal GCIPL thickness largely accounted for blood biomarker-microvascular/ERG associations.
DISCUSSION: pAD exhibits a spatially consistent, fovea-centered neurovascular and functional signature-tracking plasma tau phosphorylation and glial activation, supporting the fovea as a sensitive region in early disease-related processes.
METHODS: Thirty-eight individuals with pAD and 40 controls underwent optical coherence tomography (OCT), OCT-angiography (OCT-A), and electroretinography (ERG). Plasma p-tau217, p-tau181, glial fibrillary acidic protein (GFAP) Aβ42 and Aβ40 were quantified, adjusting for age, sex, and vascular risk factors.
RESULTS: Between-group differences were restricted to parafoveal OCT-A measures. Within the pAD group, higher p-tau217/Aβ42 and GFAP showed consistent associations with foveal measures: increased ganglion cell-inner plexiform layer (GCIPL) thickness, capillary density, altered foveal avascular zone (FAZ), and reduced photopic negative-response amplitude. These associations were absent in controls. Mediation analyses indicated that foveal GCIPL thickness largely accounted for blood biomarker-microvascular/ERG associations.
DISCUSSION: pAD exhibits a spatially consistent, fovea-centered neurovascular and functional signature-tracking plasma tau phosphorylation and glial activation, supporting the fovea as a sensitive region in early disease-related processes.